Joint Action is a podcast hosted by David Hunter.
As a consequence of isolation, those living with osteoarthritis related disability may become less fit, more depressed and anxious, more socially isolated and gain weight. It is critical at times like this that people with osteoarthritis have their burden and disability minimised and their knowledge of how to manage the disease enhanced. Join David as he interviews the world's leading experts in osteoarthritis.
Professor David Hunter is a rheumatology clinician researcher whose main research focus has been clinical and translational research in osteoarthritis. He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at University of Sydney and the Royal North Shore Hospital, Sydney, Australia. He is ranked as the worlds leading expert in osteoarthritis on Expertscape.com since 2014.
You can send in your questions to hello@jointaction.info and follow David on Instagram at @ProfDavidHunter.
To learn more about our research, visit our website at https://www.osteoarthritisresearch.com.au/
Hosted on Acast. See acast.com/privacy for more information.
Joint Action is a podcast hosted by David Hunter.
As a consequence of isolation, those living with osteoarthritis related disability may become less fit, more depressed and anxious, more socially isolated and gain weight. It is critical at times like this that people with osteoarthritis have their burden and disability minimised and their knowledge of how to manage the disease enhanced. Join David as he interviews the world's leading experts in osteoarthritis.
Professor David Hunter is a rheumatology clinician researcher whose main research focus has been clinical and translational research in osteoarthritis. He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at University of Sydney and the Royal North Shore Hospital, Sydney, Australia. He is ranked as the worlds leading expert in osteoarthritis on Expertscape.com since 2014.
You can send in your questions to hello@jointaction.info and follow David on Instagram at @ProfDavidHunter.
To learn more about our research, visit our website at https://www.osteoarthritisresearch.com.au/
Hosted on Acast. See acast.com/privacy for more information.
This week's episode is in honour of Frank Beier, who recently passed away on July 18, 2025. Frank leaves behind a remarkable legacy through the impact he made in the field of osteoarthritis. In this previous episode (2021), he discussed the recent advances in osteoarthritis understanding with a particular emphasis on novel targets and epigenetics.
Despite the large prevalence of osteoarthritis, there is no clinically approved drug which provides a cure. Currently, drugs focus on relieving symptoms such as pain. Experiments done in the laboratory have provided insight on osteoarthritis onset and progression and will likely guide therapeutic development.
We know that osteoarthritis is a disease of the whole organ meaning that any of the tissues involved in the synovial joint can be affected. The interplay between the various cell types involved is complex and understanding the interactions between cartilage, bone and synovium may be critical to therapeutic development.
Skeletal development likely plays a very important role in predisposition to disease. Through the identification of serious pathologies such as various forms of dwarfism (what in medical terms are called chondrodysplasias) the role of transcription factors and epigenetics is increasing our understanding of disease genesis.The study of the epigenetics of OA - the mechanism by which the human genome alters it’s gene expression (without changing the primary DNA sequence) has provided valuable information on novel risk factors for the disease and are potential therapeutic targets for OA.
RESOURCES
Journal articles
CONNECT WITH US
If you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!
Hosted on Acast. See acast.com/privacy for more information.